interesting article from mergermarket

Discovered this interesting article from mergermarket dated 22nd Feb 2012.

"Australian biotechs could draw foreign interest this year given maturing drug pipelines and new R&D tax credit
22 February 2012"

The 45% tax rebate could be a bonus to PRR.

Also of interest was this paragraph:

"The general consensus is that the Australian biotech industry has avoided the brunt of the financial crisis and continued to produce innovative and promising research, a local industry and academic source said. A New York-based R&D and drug development advisor agreed, noting that he had recently been approached to source anti-cancer, anti-viral and vaccine compounds from Australia."

And the last paragraph places PRR in very good light:

"Among the largest and most advanced Australian biologics companies, in addition to CSL, are USD 2bn regenerative medicine firm Mesoblast (ASX: MSB) and USD 159m cancer company Prima Biomed (ASX: PRR)."

Interesting times ahead

Here is the link to the full article:

http://www.mergermarket.com/editorial/article/1415/

Good luck to all